Answers are grounded in this paper and cite their sources.
BACKGROUND: Management of eosinophilic granulomatosis with polyangiitis (EGPA) is challenging due to inconsistent responses and frequent relapses with classic treatments. Mepolizumab (MPZ), an anti-interleukin-5 monoclonal antibody, has emerged as an effective treatment for patients with EGPA. This review assessed evidence of clinical outcomes and safety among patients with EGPA receiving MPZ in real-world settings. METHODS: A scoping review was conducted to identify real-world evidence on MPZ use in patients with EGPA. Relevant articles were identified in searches of OVID Medline and EMBASE databases alongside manual searches. RESULTS: Seventy-one references involving 51 original studies were selected for review. MPZ was administered at different dosages (predominantly 100 mg or 300 mg subcutaneously every 4 weeks) with a cumulative sample size of 2312 MPZ-treated patients. The mean duration of follow-up was 16.3 ± 9.7 months. Reported remission rates (mostly defined as a Birmingham Vasculitis Activity Score of 0 without or with low doses of glucocorticoids [GC]) ranged from 30.4% to 94.4% at 12-24 months. The overall reduction in relapse rates with MPZ ranged from 42% to 90.6%. The GC dose was significantly reduced after MPZ treatment (up to 87.2% at 16-18 months and 79.1% at 24-26 months). Approximately 50% of patients successfully discontinued GC usage at 12 months or more. No new safety signals were reported in real-world studies compared with the randomized controlled trials. CONCLUSIONS: In a real-world setting, MPZ treatment supported clinically significant benefits in patients with EGPA, with a very good safety profile.
No takes yet. Share an insight, caveat, or question.
Rúa‐Figueroa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: